Skip to main content

ALOGLIPTIN

 ALOGLIPTIN


BRAND NAME:-VIPIDIA & many brands available in INDIA


ALOGLIPTIN is an oral anti-diabetic drug in the DPP-4 (dipeptidyl peptidase-4 ) inhibitor (gliptin) class.Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.


MECHANISM OF ACTION:-

Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.


USED:- decrease the blood sugar levels 


SIDE EFFECTS:-

mild hypoglycemia based on clinical studies.Alogliptin is not associated with increased weight, increased risk of cardiovascular events. It may also cause joint pain that can be severe and disabling.




ALOGLIPTIN IS MARKETED IN JAPAN .

Labels:

Comments

Post a Comment

Popular posts from this blog

Cefpodoxime proxetil Uses, Side Effects, and More

 Cefpodoxime proxetil Brand name:- cefoprox ,cepodem,DOXCEF 100,200mg cap.  Cefpodoxime Proxetil is an antibiotic. It kills the bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive. Pharmacodynamic:-  Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Mechanism of action:-  Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicilli
Post a Comment
Read more

Cephalexin ( ZYD ) ( Cefalexin ) Uses, Side Effects, and More

 Cephalexin (ZYD) (Cefalexin) Brand name:-  Cephacillin 250,500mg cap; Sporidex, Alcephin,Cephaxin cap. Cephalexin (also called Cefalexin)  is the most common used orally effective first generation cephalosporin , similar in spectrum to cefazolin , but less active against penicillinase producing staphylococci and H. Influenza. Plasma protein binding is low; it attains High concentration in bile and is excreted unchanged in urine; t½ - 60min. Pharmacodynamic:-  Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations.Label It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis. Pharmacokinetics:- Cephalexin is rapidly and almost completely absorbed from t
Post a Comment
Read more

BASILIXIMAB Uses, Side Effects, and More

 BASILIXIMAB BRAND NAME:- Simulect   BASILIXIMAB is another anti CD - 25 antibody with higher affinity for the IL-2 receptor, but shorter plasma t½ (1 week) . is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection. PHARMACODYNAMIC:- Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.  MECHANISM OF ACTION:-  Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the trans
1 comment
Read more